The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids 177Di Marzo V, De Petrocellis L, Bisogno T, Melck D (1999b) Metabolism of anandamide and
2-arachidonoylglycerol: an historical overview and some recent developments. Lipids
34:319–325
Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin,
BR (2000a) Levels, metabolism, and pharmacological activity of anandamide in CB(1)
cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-
mediated actions of anandamide in mouse brain. J Neurochem 75:2434–2444
Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000b) Enhanced levels of
endogenous cannabinoids in the globus pallidus are associated with a reduction in
movement in an animal model of Parkinson’s disease. FASEB J 14:1432–1438
Di Marzo V, Bisogno T, De Petrocellis L (2001a) Anandamide: some like it hot. Trends
Pharmacol Sci 22:346–349
Di Marzo V, Bisogno T, De Petrocellis L, Brandi I, Jefferson RG, Winckler L, Davis JB, Dasse
O, Mahadevan A, Razdan RK, Martin BR (2001b) Highly selective CB(1) cannabinoid
receptor ligands and novel CB(1)/VR(1) vanilloid receptor “hybrid” ligands. Biochem
Biophys Res Commun 281:444–451
Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter
RD, Sugiura T, Kunos G (2001c) Leptin-regulated endocannabinoids are involved in
maintaining food intake. Nature 410:822–825
Di Marzo V, Lastres-Becker I, Bisogno T, De Petrocellis L, Milone A, Davis JB, Fernandez-
Ruiz JJ (2001d) Hypolocomotor effects in rats of capsaicin and two long chain capsaicin
homologues. Eur J Pharmacol 420:123–131
Di Marzo V, Blumberg PM, Szallasi A (2002a) Endovanilloid signaling in pain. Curr Opin
Neurobiol 12:372–379
Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T (2002b) Anandamide receptors.
Prostaglandins Leukot Essent Fatty Acids 66:377–391
DiMarzoV,GriffinG,DePetrocellisL,BrandiI,BisognoT,WilliamsW,GrierMC,Kulaseg-
ram S, Mahadevan A, Razdan RK, Martin BR (2002c) A structure/activity relationship
study on arvanil, an endocannabinoid and vanilloid hybrid. J Pharmacol Exp Ther
300:984–991
Di Marzo V, Bifulco M, De Petrocellis L (2004) The endocannabinoid system and its thera-
peutic exploitation. Nat Rev Drug Discov 3:771–784
Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi S, Kathuria S, Piomelli D (2002)
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl
Acad Sci USA 99:10819–10824
Edgemond WS, Hillard CJ, Falck JR, Kearn CS, Campbell, WB (1998) Human platelets and
polymorphonuclearleukocytessynthesizeoxygenatedderivativesofarachidonylethanol-
amide (anandamide): their affinities for cannabinoid receptors and pathways of inacti-
vation. Mol Pharmacol 54:180–188
Egertova M, Giang DK, Cravatt BF, ElphickMR (1998) A new perspective on cannabinoid sig-
nalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor
in rat brain. Proc R Soc Lond B Biol Sci 265:2081–2085
Evans RM, Scott RH, Ross RA (2004) Multiple actions of anandamide on neonatal rat
cultured sensory neurones. Br J Pharmacol 141:1223–1233
FezzaF,BisognoT,MinassiA,AppendinoG,MechoulamR,DiMarzoV(2002)Noladinether,
a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for
its quantification in rat tissues. FEBS Lett 513:294–298
Fowler CJ, Tiger G, Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Ramos JA (2003)
Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of
the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J Enzyme
Inhib Med Chem 18:225–231
Fowler CJ, Tiger G, Ligresti A, López-Rodríguez ML, Di Marzo V (2004) Selective inhibition
of anandamide cellular uptake versus enzymatic hydrolysis—a difficult issue to handle.
Eur J Pharmacol 492:1–11